Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Philadelphia chromosome (Ph)-negative B-precursor ALL, with any of the following:~  * relapsed or refractory with first remission duration less than or equal to 12 months in first salvage or~ * relapsed or refractory after first salvage therapy or~ * relapsed or refractory within 12 months of allogeneic hematopoietic stem cell transplantation (HSCT)~* 10% or more blasts in bone marrow~* In case of clinical signs of additional extramedullary disease: measurable disease~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Age ≥ 18 years~Exclusion Criteria:~* Patients with Ph-positive ALL~* Patients with Burkitt's Leukemia according to World Health organization (WHO) classification~* History or presence of clinically relevant central nervous system (CNS) pathology~* Active ALL in the CNS or testes~* Current autoimmune disease or history of autoimmune disease with potential CNS involvement~* Autologous HSCT within six weeks prior to start of blinatumomab treatment~* Allogeneic HSCT within three months prior to start of blinatumomab treatment~* Any active acute graft versus-host disease (GvHD), or active chronic GvHD Grade 2 - 4~* Any systemic therapy against GvHD within two weeks prior to start of blinatumomab treatment~* Cancer chemotherapy within two weeks prior to start of blinatumomab treatment~* Radiotherapy within two weeks prior to start of blinatumomab treatment~* Immunotherapy (e.g., rituximab) within four weeks prior to start of blinatumomab treat-ment~* Any investigational anti-leukemic product within four weeks prior to start of blinatumomab treatment~* Treatment with any other investigational medicinal product (IMP) after signature of informed consent~* Eligibility for allogeneic HSCT at the time of enrollment~* Known hypersensitivity to immunoglobulins or to any other component of the IMP formulation~* Abnormal laboratory values indicative of inadequate renal or liver function~* History of malignancy requiring treatment other than ALL within five years prior to start of blinatumomab treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix~* Any concurrent disease or medical condition that is deemed to interfere with the conduct of the study~* Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus~* Pregnant or nursing women~* Women of childbearing potential not willing to use an effective form of contraception. Male patients not willing to ensure not to beget a child~* Previous treatment with blinatumomab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).